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Abstract
Background: The common randomized controlled trial design has distinct limitations when applied to Chinese
medicine, because Chinese medicine identifies and treats ‘Chinese medicine patterns’ rather than diagnosed
diseases. Chinese medicine patterns are a group of associated symptoms, tongue appearances and pulse
characteristics. These limitations could be overcome by developing new strategies to evaluate the effect of Chinese
medicine. The idea behind pattern-based efficacy evaluations may optimize clinical trial design by identifying the
responsiveness-related Chinese medicine patterns.
Methods/Design: This is a two-stage multi-center trial of Chinese herbal medicine for the management of
rheumatoid arthritis. The stage one trial is an open-label trial and aims to explore what groups of Chinese
medicine information (such as symptoms) correlates with better efficacy, and the stage two trial is a randomized,
controlled, double-blind, double-dummy clinical trial that incorporates the efficacy-related information identified in
the stage-one trial into the inclusion criteria.
Discussion: The indication of a Chinese herbal formula is a specific Chinese medicine pattern and not a single
disease and stratifying a disease into several patterns with a group of symptoms is a feasible procedure in clinical
trials. This study is the first to investigate whether this approach in the design of Chinese herbal medicine trials can
improve responses.
Trial registration: ChiCTR-TRC-10000989
Background
Clinical trials are mainly aimed at showing the efficacy
and safety of a therapy after initial indications are deter-
mined in preclinical studies, but the results obtained
from a clinical trial have become less important in iden-
tifying the specific indications of a therapy. At present,
“-omics"-based pharmacology contributes to individua-
lized medicine, which attempts to find more specific
indications for therapies by identifying biomarkers [1].
Similarly, Chinese medicine (CM) generally prescribes
therapies based on the identification of CM patterns in
the patient by analyzing the symptoms and characteris-
tics [2].
All medicines should be rigorously tested [3,4], and
the WHO Traditional Medicine Strategy suggests that
clinical trials should be performed to establish the effi-
cacy of CM [5]. Randomized clinical trials are useful to
evaluate the efficacy of single drugs or combination
therapy in a biomedical context [6]. However, they have
distinct limitations when applied to CM because CM
treatments focus on CM pattern classification [7]. Thus,
alternative strategies, based on the CM concept, must
be developed for the evaluation of CM efficacy and
safety [8].
One important terminology in CM is “one formula
based on one pattern”, and the concept behind CM
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the responsiveness-related biocharacteristics for the
interventions [9]. Thus, in CM practice, patients with
rheumatoid arthritis (RA) can be treated with different
therapies according their different patterns, which are a
group of symptoms [10]. Therefore, the key factor in
evaluating the efficacy of herbal therapy is to find out
the specific CM pattern or indication for herbal therapy.
Although CM pattern classification is complicated and
difficult to understand in terms of making individualized
herbal combinations for patients, CM patterns for speci-
fied herbal formulae could be identified by finding out
the responsiveness-related CM information. Thus, it is
reasonable to hypothesize that the CM pattern for one
herbal therapy could be determined by comparing the
differences of CM information between the responsive
and non-responsive patients treated with the herbal
therapy.
T ot e s tt h i sh y p o t h e s i s ,w ep r o p o s eat w o - s t a g e
clinical trial sponsored by the Institute of Basic
Research in Clinical Medicine, China Academy of
Chinese Medical Sciences in China. The primary
objective of the trial was to find out the responsive-
ness-related CM symptoms that could be used as cri-
teria for inclusion into secondary clinical trials. By
comparing the difference in CM information between
the responsive and non-responsive cases treated with
one specific herbal intervention, the efficacy related
information could be identified by statistical
approaches. Secondary trials would then be aimed at
evaluating the clinical efficacy for the herbal therapy
by incorporating the efficacy related CM information
into the inclusion criteria.
Introduction to interventions
CM interventions
The combination of Chinese herbal drugs Yi Shen Juan
Bi (YSJB) and Tripterygium Wilfordii Polyglycoside
(both drugs in tablet form) are approved as herbal
medications by the State Food and Drug Administra-
tion (China) in patients with RA. Combination therapy
is recommended by the Chinese Association of Inte-
grative Medicine (unpublished data). The YSJB formula
has been recognized as a valuable CM used in the
treatment of RA. Clinically, YSJB has been shown to
ameliorate symptoms and signs of RA and to decrease
the erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), and the rheumatic factor (RF) [11].
Additionally, the mechanisms underlying the efficacy
of YSJB have been studied; YSJB significantly decreased
the production of peritoneal macrophage-derived TNF-
a, IL-1 and NO and significantly decreased prostaglan-
d i nE( P G E )a n du p - r e g u l a t e dB a xe x p r e s s i o ni nr a t
synovium [12-14]. Components of YSJB are shown in
Table 1. Tripterygium Wilfordii Polyglycoside (TWP,
dark brown pills, patent number: Z34021048) is a com-
monly used anti-rheumatic herbal drug. In CM,
extracts of Tripterygium wilfordii Hook F (TwHF,
known as “lei gong teng” or “thunder god vine”)a r e
used to treat autoimmune and inflammatory condi-
tions. Clinical trials suggest that TwHF may benefit
patients with RA [15,16].
Control interventions
The combination of methotrexate (MTX) and sulfasala-
zine (SSZ) is also a commonly used therapy for RA
treatment [17], and the combination is used as a control
in this clinical trial.
Design
This is a two-stage, multi-center trial in the manage-
ment of RA. The first-stage trial is an open-label trial
and aims to explore which groups of CM-related symp-
toms correlates with better efficacy, and the second-
stage trial is a 24-week randomized, controlled, double-
blind, double-dummy clinical trial that incorporates the
group of symptoms identified in the first-round trial in
the inclusion criteria.
The hypotheses for the two-stage clinical trial to be
tested are as follows:
Table 1 Components of Yi Shen Juan Bi (YSJB)
Chinese name Latin name
Cang Er Zi Fructus Xanthii
Congrong Herba Cistanchis
Dang Gui Radix angelica
Di Huang Radix rehmanniae
Di Long Pheretima
Gan Cao Radix Glycyrrhizae
Gu Bus Ui Rhizoma drynariae
Hu Zhang Polygoni cuspidati
Ji Xue Teng Caulis spatholobi
Jiang Can Bombyx batryticatus
Lao Guan Cao Herba erodii
Lu Xian Cao Herba pyrolae
Qiang Lang Chong Allomyrina dichotoma
Quan Xie Scorpio
Shu Di Huang Radix rehmanniae praeparata
Tu Bie Chong Eupolyphaga seu steleophaga
Wu Gong Scolopendra
Wu Shao She Zaocys (stir-fried with wine)
Xu Chang Qing Cynanchi paniculati
Xun Gu Feng Herba Aristolochiae
Yan Hu Suo Rhizoma corydalis
Yin Yang Huo Herba epimedii
Zhi Feng Fang Nidus vespae (stir-bakedg)
Zhi Feng Fang Nidus Vespae
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Page 2 of 81. The CM therapy is safe, acceptable and feasible, and
at least 80% of the subjects will complete the CM
therapy.
2. The specified group of participants treated with CM
therapy will demonstrate significantly improved ACR20
responses compared to the positive control group.
A flow chart of the study design is shown in Figure 1.
Stage one of the Trial
The first-stage trial is a 24-week open-label trial and is
aimed at exploring what CM information correlates with
better efficacy of the herbal intervention. The sample
size is 120 cases.
Inclusion criteria for participants
Eligible patients should be ≥ 18 and ≤ 70 years old and
should have been diagnosed with RA according to Ameri-
can College of Rheumatology (ACR) classification criteria
[18] and have active RA, which is defined as class I, II, or
III RA, at the time of screening [19]. Patients are allowed
to take stable doses of non-steroidal anti-inflammatory
drugs or oral corticosteroids (≤10 mg prednisone or
equivalent) ≥ 4 weeks before screening. Signed, informed
consent from a patient or guardian will be required.
Exclusion criteria for participants
Patients were excluded from the study if they received
other commercial or experimental biological therapies
Figure 1 The flowchart of the two-stage trial design.
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Page 3 of 8for RA, were diagnosed with another inflammatory dis-
ease within one month of screening, or experienced
uncontrolled or clinically significant systemic disease
other than RA. Patients diagnosed with class IV RA as
defined by ACR revised criteria for global functional sta-
tus in RA or any major chronic inflammatory disease or
connective tissue disease other than RA were also
excluded. Patients would be ineligible if they had any
laboratory abnormality that, in the opinion of the inves-
tigator, would prevent the patient from completing the
study or interfere with the interpretation of the study
results. Patients should not have received intra-articular
or systemic corticosteroid injections or any investiga-
tional therapy within 4 weeks of screening, any disease-
modifying anti-rheumatic drug other than MTX and
SSZ within 4 weeks of screening, or cyclophosphamide
within 4 weeks of the first dose of the investigational
product. Patients would be ineligible if, in the investiga-
tor’s opinion, they have any physical or psychiatric dis-
order that could interfere with their ability to give
informed consent or participate in the study. Pregnant
women would not be eligible for the study.
Intervention
Tripterygium Wilfordii Polyglycoside tablets were pro-
vided by Jiangsu Meitong Co., Ltd (Z43020138). Tripter-
ygium Wilfordii Polyglycoside or placebo were
prescribed at 10 mg 3 times a day immediately after
meals. Yi Shen Juan Bi (YSJB, dark brown pills, patent
number: ZL200510040550) is prepared by Qingjiang
Co., Ltd (Z10890004) and were prescribed at 1 pocket
(8 g) 3 times a day immediately after meals.
Outcome measures
The primary efficacy endpoint is the ACR20 response
[20] at week 24. Secondary efficacy endpoints include
the ACR50 and ACR70 responses and the individual
components of the ACR. Patterns based on CM symp-
toms, joint function, the Disease Activity Score using
the 28-joint count (DAS28), physical exam, laboratory
tests, and patient-reported outcomes, including the
Disability Index of the Health Assessment Question-
naire (HAQ) were also noted [21]. All of these end-
points over time in the study will be analyzed as
exploratory endpoints. Safety endpoints include
adverse events (AEs), serious AEs (SAEs), and labora-
tory abnormalities.
Ethical considerations
The study was conducted according to the Declaration
of Helsinki and the International Conference on Harmo-
nization Tripartite Guideline on Good Clinical Practice
[22]. Approvals from the appropriate research ethics
committees were obtained at each participating study
center. All patients were asked to provide written,
informed consent before participating.
Withdrawal criteria
Patients would be withdrawn from the study if the clini-
cian found that they were in need of or were better
served with another treatment or if the exclusion criteria
were met. Patients would also be withdrawn from the
study if according to the clinician’s judgment clinical
conditions worsened or if the patients withdrew their
consent. The date and reason for discontinuation were
noted. All patients who prematurely discontinue the
trial would undergo a final evaluation.
Recruitment
Patients were recruited through hospital advertisements,
and patients with RA would be likely to receive Chinese
herbal medicine therapies.
Setting
The trials were performed in the following hospitals:
China-Japan Friendship Hospital, Nantong Liangchun
Rheumatism Hospital, Xiangya Hospital affiliated with
Zhongnan University, Traditional Chinese Medical Hos-
pital of Xinjiang Uygur Autonomous Region, Traditional
Chinese Medical Hospital of Anhui Province, Shanxi
Taiyuan Rheumatism Hospital, Tianjin Chinese Medi-
cine College-Affiliated First Hospital, and Tongji Hospi-
tal affiliated with Tongji Medical College, Huazhong
University of Sciences and Technology.
Statistical analysis and primary results
Patients were analyzed according to the open-label study.
The primary efficacy endpoint compared the ACR20
response rate at week 24. All secondary endpoints were
pre-specified for sequential testing. The correlation
between the CM symptoms and the response, T-tests
and correlation analyses were used for the statistical ana-
lysis. For dichotomous variables, missing values were
imputed using a non-responder imputation method, and
for continuous variables, the primary analysis were based
on observed cases. Our primary result shows that the
patients with large amounts of clear urine, who sponta-
neous sweated and experienced night sweats were found
to be positively correlated with the ACR 20 response.
Further analysis shows that the ACR20 for the CM inter-
vention is 76% if only the RA patients with the efficacy
related CM symptoms could be treated with the CM
intervention, though the ACR20 is 58% in all RA patients.
Stage two of the Trial
The investigation will be a double-blind, double-dummy,
controlled study in patients with active RA aimed at
exploring the efficacy of the herbal intervention in RA
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Page 4 of 8patients with specific CM symptoms. The secondary
stage will be designed by adding the efficacy related CM
symptoms obtained from the stage-one trial as the
inclusion criteria.
Inclusion criteria for participants
To be enrolled, patients will have to meet the inclusion
criteria of stage one and have to show the efficacy
related CM symptoms from the first-stage trial. At
moment, large amounts of clear urine, spontaneous
sweated and experienced night sweats were found to be
efficacy related symptoms, and should be included in
the inclusion criteria. More analysis is still conducted
and hopefully we could find more positive clinical mani-
festations for the inclusion criteria.
Exclusion criteria for participants
The exclusion criteria will be approximately the same as
those of stage one. RA patients without the efficacy
related CM symptoms from the first-stage trial will be
excluded. Also we are conducting further analysis and
trying to find the CM symptoms which are negatively
related to the ACR20 response, and the patients with
the efficacy negatively related CM symptoms will be
excluded.
Sample size
This trial at stage 2 is designed as an active control
superiority trial and intended to show superiority of CM
intervention. The sample size calculation is based on the
A C R 2 0r e s p o n s er a t eo ft h es t a g eo n eo ft h et r i a l .T h e
p r i m a r yr e s u l t so ft h es t a g eo n et r i a l( 7 6 %A C R 2 0
response of CM intervention in the patients with the
efficacy positively related CM symptoms) and our pre-
vious clinical data (53% ACR20 response in Western
medicine intervention in the patients with the efficacy
positively related CM symptoms). The sample size was
established by comparing the rates of effectiveness
between CM and Western medicine interventions (set a
= 0.05, b= 0.10). Sample size could be 88 in both
groups. With a dropout rate for follow-up as 20%, the
sample size for each group could be 110 and 220 in the
two groups.
Randomization
Randomization will be controlled by an independent
clinical research coordinator (CRC). First, the rando-
mization form with the basic information of the par-
ticipant who passed the screening phase will be
transmitted by facsimile to the independent statisti-
cian. The randomization number in the randomiza-
tion form will be left blank before arrival at the
statistician. The statistician will then decide the ran-
domization number based on the allocation sequence,
which will be generated by a random number crea-
tion program in advance. The statistician will then
return the randomization form filled in with the
established number (specific ID number) to the CRC.
The ratio of randomization allocation to the sites
should be 1:1. The CRC will then inform the investi-
g a t o r so ft h es p e c i f i cI Dn u m b e r .T h ec o m p l e t i o no f
this procedure will be guaranteed by the research
organization.
Blinding
In this trial, investigators will not be in contact with the
CRC, the clinical pharmacist, or the statistician. The
CRC will be separated from all researchers, thus the
researchers will not have any influence on enrollment or
randomization. The statistician will receive the randomi-
zation form by facsimile, fill in the blank and return the
form; thus, any contact with other researchers will not
occur.
Setting
In this stage, 2 or more centers will be added to the list
of centers participating in the stage-one trial.
Interventions
1. Tripterygium Wilfordii Polyglycoside and its asso-
ciated placebo. To completely blind the patients, the
Tripterygium Wilfordii Polyglycoside tablet and placebo
are packaged identically. Either Tripterygium Wilfordii
Polyglycoside or the placebo will be prescribed at 10 mg
3 times a day immediately after meals.
2. Yi Shen Juan Bi (YSJB) and its associated placebo.
YSJB and its placebo are made by Qingjiang Pharmaceu-
tical Co., Ltd (Z10890004). The placebo, which has an
identical appearance, is made from cane sugar and will
be prescribed at the same dosage as the YSJB, which will
be 1 pocket (8 g) 3 times a day immediately after meals.
3. Methotrexate (MTX) and its associated placebo.
Methotrexate tablets and the placebo will be provided
by Shanghai Xinyi Pharmaceutical Co., Ltd (Drug regis-
tration Number: Z070404). MTX and its placebo are
available in 2.5-mg tablets and will be administered
orally at an initial dose of 5 mg/week (up to 15 mg/
week, 2.5 mg/per time). For the remission period, the
standard dose will range from 1 tablet/week (2.5 mg) to
3 tablets/week (7.5 mg).
4. Sulfasalazine (SSZ) and its associated placebo. Sulfa-
salazine tablets and the placebo were provided by Xi’an
Kangbaier Pharmaceutical Co., Ltd (Drug registration
Number: Z070404). SSZ and its placebo are available in
0.25 g tablets and will be taken at an initial dose of 0.25
g twice a day (up to 0.5-1 g, 4 times/day). For the remis-
sion period, the standard dose will be 0.5 g (2 tablets) 3-
4 times/day.
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gium Wilfordii Polyglycoside and YSJB along with the
MTX and SSZ placebos. Participants in the positive con-
trol therapy will be given MTX and SSZ (Western com-
bination therapy) along with the Tripterygium Wilfordii
Polyglycoside and YSJB placebos.
Outcome measures
The primary efficacy endpoint is the ACR20 response.
Secondary efficacy endpoints include the ACR50 and
ACR70 responses and the individual components of the
ACR. CM symptoms, joint function, physical exam,
laboratory tests, and HAQ will be tested. Safety end-
points include AEs and laboratory abnormalities. The
timeline of the participants’ progression through the
trial in stage two is shown in Table 2.
Ethical considerations
Approvals from the appropriate research ethics commit-
tees will be obtained at ten study centers. All patients
will be asked to provide written, informed consent
before participating.
Quality control
The identification, registration and subsequent flow of
participants in the trial will be governed by the trial
standard operational protocol (SOP) at all sites. The
sites’ Case Report Form (CRF) completion and compli-
ance with standard operation procedures will be audited.
Clinical research associates, at regular periods, will
monitor the clinical trial procedures, such as compliance
with administration and voluntary withdrawal of partici-
pants. In particular, the reasons for withdrawal will be
fully documented in the CRF.
Statistical analysis
Patients will be included for analysis according to the
randomized treatment arm regardless of the actual treat-
ment received during the study. All efficacy endpoints
will be analyzed using the intent-to-treat analysis set,
Table 2 Timeline of participants’ progression through the stage-two trial
Assessment Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9
Screen Base 2
nd w* 4
th w8
th w1 2
th w1 6
th w2 0
th w2 4
th w
(or withdrew)
Medical history ●
Physical examination ●● ● ● ● ● ● ●
Joint function ●●●●●●● ●
Swollen joint count ●●●●●●● ●
Tender joint count ●●●●●●● ●
Physician global status ●●●●●●●● ●
Patient global assessment ●●●●●●● ●
Morning stiffness ●●●●●●● ●
Pain at rest ●●●●●●● ●
Pattern based on CM
(symptoms)
●●●●●●●● ●
Blood test ●●● ● ●
Routine urine test ●●● ● ●
Stool routine test ●● ●
CRP ●● ●
ESR ●● ●
RF ●● ●
ALT ●●● ● ●
AST ●●● ● ●
Bilirubin ●● ●
Cr ●●● ● ●
BUN ●●● ● ●
VAS ●● ● ● ● ● ●
HAQ ●● ●
EGG ● ●
X-ray ● ●
Adverse events ●●●●●●● ●
Notes: *w = week
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whether they received an investigational product. The
safety dataset will also include all patients who received
≥ 1 dose of an investigational product. The primary effi-
cacy endpoint will be used to compare the ACR20
response rate at week 24 in the CM group with that of
the biomedicine group. All secondary endpoints will be
tested sequentially in a pre-specified order to control
the one-error rate at 5% (two-sided). The comparisons
of proportions (for dichotomous variables) among treat-
ment arms will be performed using Fisher’se x a c tt e s t .
For dichotomous variables, missing values will be
imputed using a non-responder imputation method; for
continuous variables, the primary analysis will be based
on observed cases.
Discussion
In the application of Chinese herbal medicine, many sys-
tematic reviews report that it is difficult to show rigor-
ous evidence for the effectiveness of herbal medicine
[23,24], even though Chinese herbal medicine has been
used for over 3000 years in China and its effectiveness
is based on thousands of years of observation and clini-
cal practice. The reasons for this difficulty might be that
the indication of a Chinese herbal medicine requires
specification with CM pattern differentiation, which
means that a Chinese herbal medicine should show its
best effectiveness only in part of a population of patients
with a specific disease.
The specific subpopulation of the patients could be
identified with CM pattern classification principles.
However, there are two questions in applying pattern
classification to identify this subpopulation of patients.
Firstly, the CM information for pattern classification,
such as CM symptoms, the appearance of the tongue
and the pulse, is not focused on biomedicine or is diffi-
cult for many biomedical practitioners to understand.
Secondly, though the herbal products or a fixed herbal
formula for efficacy evaluation would have its relative
fixed CM pattern, it is still difficult to specify the exact
CM pattern and identify the CM information for the
pattern. In real CM clinical practice, the herbal prepara-
tions could be changed with additions or subtractions of
the previous herbal combinations, and the changes in
the herbal preparation are mainly based on the
responses after the intervention. In that sense, the main
concept in CM pattern identification would be that the
specific CM pattern for an intervention could be deter-
mined as effectiveness-related factors by comparing the
responsive and non-responsive cases based on the CM
information. The effectiveness-related factors could be
obtained by comparing the differences between the
effective cases and non-effective cases if there was
enough information in the clinical trial. Many non-
diagnostic-related symptoms on which Chinese medicine
focuses (such as thirst in rheumatoid arthritis or heavy
limbs in diabetes), non-diagnostic laboratory measure-
ments, and pharmaco-omics information used to deter-
mine the individual therapy can be collected for the
comparison between the responsive and non-responsive
cases [25,26]. At present, more attention is focused on
“-omics” information for individualized therapy, and we
believe that TCM information, with its effectiveness in
long-term clinical practice, could be more feasible for
clinical trials. Our previous analysis of a randomized
clinical trial on an herbal product for the treatment of
rheumatoid arthritis shows that some non-diagnostic
symptoms correlated with the effectiveness of the drugs
and that the effectiveness would be higher if the corre-
lated information were re-analyzed [27].
The ingredients in herbal products, with their relative,
fixed-CM pattern feature, cannot be changed after the
product is marketed. Thus, there is a dilemma in evalu-
ating the efficacy of CM herbal products; the CM pat-
tern is important for the evaluation, but it is difficult to
understand. This two-stage clinical trial was designed to
evaluate the efficacy of CM therapy (biomedical inter-
vention could be included in terms of indication specifi-
cation) based on the CM pattern identification concept,
and the CM patterns could be identified by comparing
the CM information between the responsive and non-
responsive cases during the first-stage clinical trial.
YSJB and TWP are commonly used for the treatment
of RA in CM, and the combination therapy with MTX
and SSZ are also commonly used in biomedicine. In
routine clinical trials, YSJB and TWP show less effective
in RA treatment compared to biomedical intervention
(unpublished data) because it is hard to incorporate CM
pattern information in trials. The findings from the
stage-one trial suggested that the group of patients with
some CM symptoms have improved efficacy, and the
stage-two clinical trial was designed by adding the
group of symptoms selected in the first stage trial for
inclusion criteria in the second trial. We hope that the
ACR20 response can be improved in RA treatment with
CM therapy due to the CM pattern classification con-
cept utilized in the trial.
It is anticipated that this two-stage trial will take 24
months to complete. The first-stage trial is completed,
and recruitment into the second-stage trial commenced
in June 2010 with the first participant randomized in
August 2010. The 24-week follow-up assessments will
be completed in the end of 2011.
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